Accent Therapeutics
Focus: Accent Therapeutics is a public biotech company focused on developing RNA-modifying protein inhibitors for gene therapy applications. The company is in early-stage development with a lean pipeline targeting oncology indications.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Accent Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Accent Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ATX-295
Advanced Solid TumorsClinical Trials (1)
NCT06799065First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Phase 1Help build intelligence for Accent Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.